Skip to main content

Table 4 Comparison of molecular profile of each intrinsic subtype

From: The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

 

ER/PR + HER2-

ER/PR + HER2+

HER2 type

Basal-like

Unclassified

n

OR

n

OR

n

OR

n

OR

n

OR

EGFR

Positive

16

1.0 (Ref)

5

2.77 (0.69, 9.44)

19

9.64 (3.76, 20.53)

34

104.55 (41.51, 856.77)

0

0.00 (0.00, 2.75)

Negative

283

 

35

 

39

 

3

 

28

 

PTEN

Reduced

156

1.0 (Ref)

18

0.75 (0.35, 1.55)

16

0.31(0.16, 0.63)

28

2.57 (1.11, 6.37)

16

1.31 (0.55, 3.15)

Normal

140

 

23

 

42

 

9

 

12

 

Bcl- 2

Positive

249

1.0 (Ref)

27

0.41 (0.19, 0.99)

7

0.02 (0.01, 0.07)

6

0.04 (0.01, 0.12)

14

0.20 (0.08, 0.49)

Negative

51

 

13

 

51

 

31

 

14

 

c -Kit

Positive

15

1.0 (Ref)

0

0.00 (0.00, 2.16)

7

2.70 (0.84, 7.48)

10

7.50 (2.60, 20.96)

1

0.73 (0.02, 5.29)

Negative

287

 

41

 

51

 

27

 

27

 

c- Met

Positive

203

1.0 (Ref)

34

1.98 (0.79, 5.54)

47

2.63 (1.14, 6.70)

28

1.43 (0.61, 3.60)

16

0.58 (0.23, 1.44)

Negative

89

 

7

 

8

 

9

 

11

 

Survivin

Positive

240

1.0 (Ref)

34

1.32 (0.50, 4.20)

56

7.54 (1.74, 61.08)

30

1.25 (0.05, 3.52)

23

1.41 (0.46, 4.91)

Negative

62

 

6

 

2

 

7

 

5

 
  1. Results are odds ratio (OR) adjusted by age and 95% confidence interval.
  2. EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor.